T nexito plus
Reading File
Finding Sources
Finding Sources
Searching the Web
Nexito Plus escitalopram clonazepam uses dose side effects
Reading File
Reading File
Reading File
Reading Web Page
https://www.1mg.com/drugs/nexito-plus-tablet-153851
Here is a complete overview of Nexito Plus:
Nexito Plus
Manufacturer: Sun Pharma
Category: Combination antidepressant + anxiolytic
Composition
| Component | Dose per tablet |
|---|---|
| Escitalopram (SSRI) | 5 mg or 10 mg |
| Clonazepam (Benzodiazepine) | 0.5 mg |
Mechanism of Action
Escitalopram (S-citalopram)
Escitalopram is the pure S-enantiomer of citalopram. It is the "quintessential SSRI" - it works by selectively inhibiting the serotonin reuptake transporter (SERT), increasing synaptic serotonin. Unlike racemic citalopram, the removal of the R-enantiomer means:
- No antihistaminic side effects
- No dose-related QTc prolongation at therapeutic doses
- More predictably efficacious at the lowest dose
- Fewest CYP450-mediated drug interactions among SSRIs
(Stahl's Essential Psychopharmacology)
Clonazepam (Benzodiazepine)
Clonazepam is a high-potency, intermediate- to long-acting benzodiazepine. It acts as a positive allosteric modulator of GABA-A receptors, potentiating the inhibitory effect of GABA. This produces:
- Anxiolytic effect
- Anticonvulsant effect
- Muscle relaxation
- Sedation
Peak plasma: 1-4 hours | Half-life: 20-60 hours (mean ~30 hours)
(Maudsley Deprescribing Guidelines)
Indications
- Depression with comorbid anxiety
- Generalized anxiety disorder (GAD)
- Panic disorder
- Social anxiety disorder
The combination is designed for patients who need rapid anxiolysis (clonazepam kicks in quickly) while the SSRI builds up over 2-4 weeks to provide sustained antidepressant and anti-anxiety effects.
Pharmacokinetics of Escitalopram
| Parameter | Value |
|---|---|
| Oral bioavailability | ~80% |
| Time to peak (Tmax) | ~5 hours |
| Protein binding | ~56% |
| Half-life | 27-32 hours |
| Steady-state | ~7 days |
| Metabolism | CYP2C19 (primary), CYP3A4 (minor) |
| Renal clearance | ~7% |
Dose adjustment needed in: elderly (use 10 mg/day max), hepatic impairment (use lower dose).
(Kaplan & Sadock's Comprehensive Textbook of Psychiatry)
Dosage
- Typically taken once daily, with or without food, preferably at the same time each day
- Available in Nexito Plus 5/0.5 mg and Nexito Plus 10/0.5 mg formulations
- Dose is titrated as per clinical response; do not exceed prescribed dose
Side Effects
Common
- Drowsiness / sedation
- Delayed ejaculation
- Low libido / sexual dysfunction
- Nausea, vomiting
- Dizziness
- Headache
- Insomnia or excessive sedation
- Memory impairment / confusion
- Lethargy / fatigue
- Weight changes (gain or loss)
Serious (monitor for)
- Suicidal ideation - especially in young adults early in treatment (black box warning for SSRIs)
- Dependence and withdrawal - clonazepam carries an FDA boxed warning; physical dependence can develop within days to weeks
- Serotonin syndrome - if combined with other serotonergic agents
- Respiratory depression - with alcohol or other CNS depressants
Contraindications
- Concurrent use of MAO inhibitors (risk of serotonin syndrome)
- Pregnancy - generally contraindicated; may harm the fetus
- Breastfeeding - escitalopram passes into breast milk; caution required
- Severe renal/hepatic impairment
- Angle-closure glaucoma (escitalopram risk)
Important Warnings & Precautions
| Situation | Caution |
|---|---|
| Alcohol | Strictly avoid - potentiates CNS depression, worsens dizziness and sedation |
| Driving/machinery | Avoid - clonazepam causes drowsiness and impaired coordination |
| Abrupt discontinuation | Do NOT stop suddenly - risk of benzodiazepine withdrawal (seizures, anxiety) and SSRI discontinuation syndrome |
| Elderly | Use lower doses; increased risk of falls and sedation |
| Kidney disease | Dose adjustment may be required |
| Liver disease | Reduced clearance; use with caution |
Key Drug Interactions
- MAOIs - contraindicated (serotonin syndrome)
- Alcohol / CNS depressants - enhanced sedation and respiratory depression
- CYP2C19 inhibitors (e.g., omeprazole, fluconazole) - increase escitalopram levels
- Other serotonergic drugs (triptans, tramadol, linezolid) - serotonin syndrome risk
- Anticoagulants (warfarin) - SSRIs may increase bleeding risk
Clinical Notes
- The clonazepam component is intended for short-term use (the manufacturer states efficacy data beyond 9 weeks is limited). Long-term combination use is generally not recommended; the SSRI alone should be continued after stabilization.
- Do not stop clonazepam abruptly - taper slowly using hyperbolic dose reductions to minimize withdrawal symptoms (Maudsley Deprescribing Guidelines).
- Nexito Plus should be continued for the full prescribed course even if symptoms improve early.
Sources: Stahl's Essential Psychopharmacology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Maudsley Prescribing & Deprescribing Guidelines; PharmEasy/1mg drug monographs
Tab Solitin 5mg
Finding Sources
Searching the Web
Solitin 5mg solifenacin succinate uses dose side effects India
Reading File
Reading Web Page
https://pharmeasy.in/online-medicine-order/soliten-5mg-table…
Reading File
Here is a complete overview of Tab Solitin 5mg:
Tab Solitin 5mg (Solifenacin Succinate)
Generic name: Solifenacin succinate
Brand names in India: Solitin, Soliten, Soliris, Solif
Category: Antimuscarinic / Anticholinergic - Urinary antispasmodic
Manufacturer: Sun Pharma (various)
Composition
| Component | Dose |
|---|---|
| Solifenacin succinate | 5 mg per tablet |
Also available as 10 mg tablet.
Mechanism of Action
Solifenacin succinate (YM905) is a tertiary amine with selective M3 muscarinic receptor antagonism (with modest selectivity for M3 over M2 and M1 receptors). It works by:
- Blocking M3 muscarinic receptors on detrusor (bladder wall) smooth muscle - prevents abnormal involuntary contractions
- Increasing bladder capacity - allows the bladder to hold more urine before the urge to void
- Effects on sensory function - increases the area under the bladder-volume sensation curve, meaning urgency sensations are dampened
The net result is: fewer involuntary bladder contractions, increased voiding intervals, reduced urgency and frequency.
(Campbell-Walsh-Wein Urology)
Pharmacokinetics
| Parameter | Value |
|---|---|
| Bioavailability | ~90% (well absorbed orally) |
| Time to peak (Tmax) | ~3-8 hours |
| Protein binding | ~98% |
| Half-life | 45-68 hours |
| Metabolism | Hepatic - CYP3A4 |
| Elimination | Renal and fecal |
| Steady-state | ~10 days |
The long half-life allows once-daily dosing.
(Campbell-Walsh-Wein Urology)
Indications
- Overactive bladder (OAB) with symptoms of:
- Urinary urgency (sudden, strong urge to urinate)
- Urge urinary incontinence (leakage with urgency)
- Urinary frequency (urinating too often, >8 times/24 hrs)
- Nocturia (waking at night to urinate)
Dosage
| Setting | Dose |
|---|---|
| Standard adult dose | 5 mg once daily |
| If well tolerated and response inadequate | May increase to 10 mg once daily |
| Severe renal impairment (CrCl <30 mL/min) | Maximum 5 mg/day |
| Moderate hepatic impairment | Maximum 5 mg/day |
| Severe hepatic impairment | Contraindicated |
- Take with or without food, swallow whole
- Take at the same time each day
- Maximum benefit seen at 4 weeks; onset of improvement may be sooner
Clinical Efficacy
In large phase III trials, solifenacin 5 mg significantly reduced:
- Micturition frequency (-2.21 micturitions/day vs -1.03 placebo)
- Urgency episodes
- Incontinence episodes
- Volume voided per micturition increased
Solifenacin was non-inferior to tolterodine for micturition frequency but showed significantly greater efficacy for urgency/incontinence. (Campbell-Walsh-Wein Urology)
Side Effects
Common (anticholinergic effects)
- Dry mouth (most common, ~10-28%)
- Constipation
- Nausea, stomach pain, indigestion
- Blurred vision / visual accommodation difficulty
- Urinary retention (less common)
- Drowsiness / fatigue
- Dry eyes
Serious (rare)
- Acute urinary retention - especially in men with BPH
- Angioedema
- QT interval prolongation (at high doses)
- Cognitive impairment (elderly patients - anticholinergic burden)
- Hallucinations / confusion (rare, elderly)
Contraindications
- Urinary retention (current)
- Gastric retention / severe GI motility disorders
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment (Child-Pugh C)
- Myasthenia gravis
- Hypersensitivity to solifenacin
Precautions & Warnings
| Situation | Caution |
|---|---|
| Elderly | High anticholinergic burden - risk of falls, cognitive decline, confusion |
| Benign prostatic hyperplasia (BPH) | Risk of urinary retention - use with care |
| Pregnancy | Limited data - use only if clearly necessary |
| Breastfeeding | Excreted in breast milk - avoid |
| Driving | May cause blurred vision and drowsiness - caution |
| Alcohol | Worsens OAB symptoms and may increase CNS effects - avoid |
| Renal impairment | Dose cap at 5 mg/day if severe |
| Hepatic impairment | Dose cap at 5 mg/day if moderate; contraindicated if severe |
Drug Interactions
| Drug | Interaction |
|---|---|
| CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) | Increase solifenacin plasma levels significantly - use with caution or reduce dose |
| CYP3A4 inducers (rifampicin, carbamazepine) | Reduce solifenacin efficacy |
| Other anticholinergics | Additive anticholinergic side effects |
| Mirabegron | Combination used for refractory OAB (evidence-based: SYMPHONY trial) - effective and generally well tolerated |
| QT-prolonging drugs | Additive QT risk - use with caution |
Combination Use
Solifenacin 5 mg + Mirabegron 50 mg (beta-3 agonist) combination has strong evidence for refractory OAB patients who do not respond adequately to monotherapy. This combination works through complementary mechanisms and is endorsed by urology guidelines. (Campbell-Walsh-Wein Urology)
Key Clinical Points
- Take for at least 4 weeks before assessing full benefit
- Do not stop abruptly without consulting your doctor
- Monitor for urinary retention, especially in elderly men
- Due to the anticholinergic burden, use with caution in elderly patients (risk of cognitive decline with long-term use)
- Preferred over older antimuscarinics (oxybutynin) due to better tolerability and selectivity
Sources: Campbell-Walsh-Wein Urology; PharmEasy/Soliten drug monograph
Inj amphoterium B
Finding Sources
Searching the Web
Amphotericin B injection uses dose side effects nephrotoxicity liposomal
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.